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A B S T R A C T
Objective: A signiﬁcant number of HIV-1 patients experience poor immune reconstitution despite long-
term viral suppression with highly active antiretroviral therapy (immunological non-responders). The
aims of the present study were to determine whether eradication of Helicobacter pylori could facilitate a
better immune reconstitution in these patients.
Methods: Forty-nine immunological non-responder HIV-1 patients were evaluated by 13C-urea breath
test (UBT) for the presence of active H. pylori infection. They were all asymptomatic. The UBT was
positive in 26 (53%) of them. Eleven patients (group 1) were treated with a combination of omeprazole
20 mg bid, amoxicillin 1 g bid and clarithromycin 500 mg bid for 14 consecutive days. Eight weeks later,
successful eradicationwas proven by a repeat negative UBT in all 11 patients. The remaining 15 (group 2)
refused the H. pylori eradication treatment. All 26 patients were followed for 24 months and evaluated
for blood CD4 and CD8 cell counts and percentages and for plasma HIV-1 viral load.
Results: At the time of H. pylori diagnosis and eradication (baseline), CD4 and CD8 cell counts were
similar in both study groups. All 11 H. pylori eradicated patients (group 1) had a signiﬁcant increase in
CD4 cell count starting 3 months and peaking 12–18 months after H. pylori eradication. Thereafter, CD4
levels gradually declined. Nevertheless, 24 months after triple therapy it was signiﬁcantly higher than
prior toH. pylori eradication. Parallel reciprocal changes were observed in CD8 cell counts. There were no
signiﬁcant changes in either CD4 or CD8 cell counts in group 2 patients. None of the patients of group 1
demonstrated virological failure, while four (26.7%) group 2 patients experienced virological failure
requiring change of highly active antiretroviral therapy (HAART) regimen.
Conclusion: Triple therapy for H. pylori eradication is associated with a signiﬁcant, although possibly
transient immune reconstitution in HAART-treated HIV-1 patients with viral suppression without
immunological response.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Highly active antiretroviral therapy (HAART) has dramatically
improved the prognosis of patients infected with HIV-1. In the
majority of HIV-1 infected patients under HAART, plasma viral load
becomes undetectable (low detectable level, LDL) and CD4 cells
increase to near normal levels over time. Nevertheless, in a portion
of the patients, a discrepancy between plasma viral load and the
immune status is observed. In this population, CD4 cell counts do
not increase despite full plasma viral load suppression (immuno-
logical non-responders).1 Approximately one-third of patients* Corresponding author. Tel.: +972 8 6745710; fax: +972 8 6745712.
E-mail address: allergologycom@gmail.com (E. Magen).
1 Both authors have equal contribution to the article.
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.03.036receiving HAART for 5 years or more will not reach CD4 cell counts
above 500 cells/mm3 despite continuous suppression of plasma
HIV-1 RNA.2 Moreover, CD4 cell counts may remain < 200 cells/
mm3 in 10–20% of treated individuals.3
The level of immune reconstitution in patients with undetect-
able HIV-1 viral load depends on several factors (e.g., low CD4+ cell
count at the initiation of HAART, advanced stage of disease). There
is no deﬁnitive evidence that age, viral strain/clade, or host genetic
factors play a role in these different responses to HAART.4,5 The
association of CD4 cell nadir with the extent of immune
reconstitution in HIV-1-infected individuals suggests that the
infection may cause irreparable immune system damage despite
HAART.6 The permanent HIV-1 replication in lymphoid tissues,
despite undetectable plasma viral load, has also been proposed as
an underlying mechanism for cellular activation and impaired T
cell reconstitution.7 An inadequate production of interleukin (IL)-2ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Demographic and immunological characteristics at baseline (time of Helicobacter
pylori diagnosis/eradication)
Group 1a Group 2a p-Value
Number of patients (male/female) 11 (6/5) 15 (7/8) NS
Age (years) 44.515.5 45.213.9 NS
Time from HIV diagnosis, years 5.92.4 6.22.8 NS
Cell counts and percentagesb
CD4 cells/mm3 220.3111.9 241.4120.8 NS
CD4% 15.68.5 16.87.8 NS
CD8 cells/mm3 698.3158.7 736.5187.2 NS
CD8% 68.312.7 70.116.8 NS





AZT+3TC+NFV 4 (36.4) 3 (20)
D4T+3TC+NFV 1 (9.1) 2 (13.3)
AZT+3TC+ IDV 0 (0) 1 (6.7)
AZT+3TC+ IDV/RTV 2 (18.2) 3 (20)
D4T+3TC+ IDV/RTV 1 (9.1) 2 (13.3)
AZT+3TC+EFV 2 (18.2) 3 (20)
AZT+3TC+NVP 1 (9.1) 1 (6.7)
Results are mean standard deviation or n (%) unless otherwise stated.
a Group 1: 11 patients who underwent successful Helicobacter pylori eradication
with triple therapy; group 2: 15 patients who refused H. pylori triple therapy. All
patients had H. pylori co-infection as determined by a positive urea breath test and
were deﬁned as immunologic non-responders.
b Cell counts and percentages at baseline.
c HAART (highly active antiretroviral treatment): AZT, zidovudine (300mg bid);
3TC, lamivudine (150mg bid); D4T, stavudine (40mg bid); NFV, nelﬁnavir (750mg
tid); IDV, indinavir (400mg tid); IND/RTV, indinavir 400mg/ritonavir 100mg bid;
EFV, efavirenz (600mg qd); NVP, nevirapine (200mg bid).
E. Magen et al. / International Journal of Infectious Diseases 14 (2010) e322–e327 e323and IL-7 in patients with a long-term HIV-1 infection has been
reported to play a role in the lack of CD4 cell increase. Therefore, IL-
2 treatment is currently considered a therapeutic option for HIV-1
infected patients with low CD4 cell counts.8 Furthermore, the
baseline immune activation state predicts CD4 cell recovery during
viral suppression.9 In addition, co-infection of several pathogens
(e.g., hepatitis C virus) with HIV-1 has been shown to be
responsible for enhanced immune activation and may contribute
to disease progression and failure of immune reconstitution.10,11
Helicobacter pylori infect the stomach in half of the human
population worldwide, causing chronic gastritis, which can lead to
peptic ulcer disease, gastric adenocarcinoma, and mucosa-
associated lymphoid tissue lymphoma.12H. pylori triggers vigorous
humoral and cellular immune responses in both systemic and
mucosal compartments. In spite of this response, the vast majority
of infected hosts are unable to clear the infection, and it persists for
decades.13
The aims of our study were to assess the prevalence of H. pylori
infection among immunologic non-responder HIV-1-infected
patients and to assess the possible efﬁcacy of H. pylori eradication
on immune reconstitution in this population.
2. Materials and methods
2.1. Study population
Patients were selected from the computerized database of the
Neve Or AIDS Center (the biggest AIDS center in Israel). Research
staff screened the center’s database and examined the medical and
laboratory records to identify HIV-1 patients who had been on
HAART for at least 12 months, and who had failed to elevate their
CD4 cell count (DCD4 <10% after 12 months of HAART) and
remained <300 cells/mm3 despite a relatively longstanding (>12
months) plasma HIV-1 suppression (RNA <400 copies/ml). These
patients were deﬁned as immunological non-responders. Only
patients who met these inclusion criteria were included in the
present study. A total of 1284HIV-infected subjects, 60.7%male and
39.3% female,were found inourcenter registry. Sevenhundredﬁfty-
twoofour patients (58.8%male:median age39 (range18–74) years;
41.2% female:median age 35 (range 18–64) years) had been treated
with HAART for at least 12 months, with regular periodic (every 3
months) determinations of plasma viral load and CD4 cell count.
Forty-nine (6.5%) of these patients met the criteria for immunolo-
gical non-responder. All 49patientswere evaluated for the presence
ofH. pylori infection by 13C-urea breath test (UBT). Twenty-six of 49
(53%) revealedapositiveUBT suggestinganactiveH. pylori infection.
All 49 patients did not have peptic symptoms (asymptomatic H.
pylori carriers). At this point, we offered all 26 H. pylori-infected
patients a course of triple therapy (a combination of omeprazole
20 mgbid, amoxicillin 1 g bid and clarithromycin 500 mgbid) for 14
consecutive days. Eleven patients (42% of H. pylori-infected HIV-1
patients) agreed and completed H. pylori eradication treatment
(group 1). The success of H. pylori eradication was conﬁrmed by a
repeat negative UBT, which was done 8 weeks following the
termination of the triple therapy. Fifteen patients (58%) refused H.
pylori eradication treatment despite our recommendation (group2).
All 26 patients were than followed at our center for at least 24
months, with a periodic (every 3 months) determination of plasma
HIV-1viral load,CD4andCD8cell counts. The clinical and laboratory
follow-up of the 26 patients (groups 1 and 2) were similar to the
routine follow-up of all HIV-1-infected patients at our center
(according to the accepted standard of care). Clinical and laboratory
data (12 months prior and 24 months following H. pylori diagnosis/
eradication)were obtained retrospectively fromthe center database
with the approval of the Kaplan Medical Center Ethics Committee.2.2. 13C-urea breath test (UBT)
The 13C-urea breath test (UBT) for H. pylori was performed in
the central laboratory of Clalit Health Services, Israel. Trained
nurses in regional laboratories performed theUBT, and the samples
were analyzed by a mass spectrometer (Analytical Precision 2003,
UK). The patientswere given 75 mg urea labeledwith 13C in 200 ml
of orange juice, and breath samples were collected before 13C
intake (T0) and 30 min later. The cut-off 12C/13C at T0 and T30 time
pointswas 3.5, in accordancewith themanufacturer’s instructions.
2.3. Lymphocyte phenotype analysis
Fluorescence activated cell sorting (FACS) analysis (FACScan,
Becton Dickinson Immunocytometry Systems, San Jose, CA, USA)
wasperformedonwholeheparin-anticoagulatedbloodwithin3 hof
blood collection. A mixture of one to three of the following
monoclonal antibodies, conjugated with either ﬂuorescein isothio-
cyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein
(PerCP) or Cy-Chrome, directed against CD3, CD4 and CD8,was used
for the determinations of the relevant subpopulations of T cells.
2.4. Determination of viral load
The HIV plasma viral load was determined by an automated
Amplicor polymerase chain reaction and Amplilink software
(Cobas Amplicor, Roche Diagnostics, Branchberg, NJ, USA).
Virologic failure was deﬁned as plasma HIV-1 RNA 400 copies/
ml in two consecutive determinations after viral suppression (HIV-
1 RNA <400 copies/ml).
2.5. Statistical analysis
Results are presented as mean  standard deviation (SD). The
non-parametric Mann–Whitney test and unpaired Student’s t-test
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statistically signiﬁcant.
3. Results
The baseline characteristics of our study population are
presented in Table 1. As can be seen in the Table, at the time of
H. pylori diagnosis, the demographic (gender, age, time from
HIV-1 diagnosis) and immunological (CD4 and CD8 cell counts
and percentages) parameters were similar in both study groups
(group 1: 11 patients who underwent successful H. pylori
eradication, as deﬁned by repeat negative UBT, which was done
8 weeks following the termination of H. pylori triple therapy, and
group 2: 15 patients who refused triple therapy for H. pylori). In
addition, the duration and nature of HAART regimens prior to
the time of H. pylori diagnosis were similar in both study groups
(Table 1). All patients, in both study groups, revealed HIV-1
suppression (plasma viral load <400 copies/ml) at baseline and
during the prior 12 months. In spite of the prolonged (12
months) HIV-1 suppression, these patients (groups 1 and 2)
were deﬁned as immunological non-responders since their CD4
cell counts were below 300 cells/mm3 and/or had not increased
by more then 10% per year compared to the levels prior to
HAART initiation.Figure 1. CD4 cell counts and percentages in the two study groups during the follow-up p
months following the diagnosis of Helicobacter pylori. Group 1: 11 patients treated with
refused triple therapy. Time 0 indicates the time of H. pylori diagnosis and eradication. T
analyze CD4 cell counts and percentages at all time points to priormeasurements (e.g., be
eradication. The absence of star means no statistical signiﬁcance (p = NS). *p< 0.05 betwe
(12 to 0 months). **p < 0.05 compared to previous measurement. ***p < 0.0001 compTwenty-four months of follow-up of our study patients clearly
demonstrated a signiﬁcant increase in both CD4 cell counts and
percentages in all 11 patients in group 1 following their successful
H. pylori eradication (Figure 1). The CD4 cell counts (and
percentages) started to increase at 3 months and peaked at 12–
18months afterH. pylori triple therapy. Thereafter, CD4 cell counts
(and percentages) gradually declined. Nevertheless, at the end of
the study, 24 months after H. pylori eradication, the CD4 levels
(counts and percentages) were signiﬁcantly higher compared to
the levels during the 12 months prior to H. pylori eradication
(Figure 1). Reciprocal signiﬁcant changes in CD8 cell counts and
percentages were observed in group 1 patients following H. pylori
triple therapy (Figure 2). In contrast, no such changes in either CD4
or CD8 cell countswere observed in group 2 patients (Figures 1 and
2) or in the 23 H. pylori-negative HIV-1-infected immunological
non-responder patients (data not shown).
None of the 11 patients in group 1 demonstrated virological
failure (as deﬁned in the Materials and methods) during the 24-
month follow-up period. In contrast, four (26.6%) from group 2 and
two (8.7%) from the 23 H. pylori-negative group of patients,
revealed virological failure requiring change of their HAART
regimen. During the follow-up period there were no signiﬁcant
differences in either CD4 or CD8 cell counts between group 2
patients with virological failure and those without.eriod. CD4 cell counts and percentages at 12months (12 to 0) prior and 24 (3 to 24)
triple therapy resulting in successful H. pylori eradication; group 2: 15 patients who
he non-parametric Mann–Whitney test and unpaired Student’s t-test were used to
tween 3 and 0, 18 and 12months) and to the levels prior toH. pylori diagnosis and/or
en all time points followingH. pylori eradication (3–24months) and the prior levels
ared to previous measurement.
Figure 2. CD8 cell counts and percentages in the two study groups during the follow-up period. CD8 cell counts and percentages prior (time 0) and 24 months after
Helicobacter pylori diagnosis and eradication. Group 1: 11 patients treated with triple therapy with successful H. pylori eradication; group 2: 15 patients who refused triple
therapy. The non-parametric Mann–Whitney test and unpaired Student’s t-test were used to analyze CD8 cell counts and percentages to prior measurements (e.g., 12 to 6
months) and at all time points to the levels prior to H. pylori eradication (time 0). The absence of star means no statistical signiﬁcance (p = NS). *p < 0.05 at all time points (3–
24 months) following H. pylori eradication to time 0. **p < 0.05 between months 18 and 12. ***p < 0.0001 compared to previous measurement.
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Our study demonstrates remarkable therapeutic effects of H.
pylori eradication on immune reconstitution in HIV-1-infected
patients with inadequate immunological response despite virolo-
gical suppression under HAART (immunological non-responders).
Several studies indicate a lower prevalence ofH. pylori infection
in HIV patients as compared to the general population.14–18 In
contrast, other studies have reported similar prevalence ofH. pylori
infection in HIV-1-positive and negative populations.18,15,16,17
Moreover, no association between the prevalence of H. pylori
infection and patient age, sex, risk group, or the type of HAART
regimen has been demonstrated,18,19 though it appears that the
prevalence of H. pylori infection decreases concomitantly with the
decrease in CD4 cell count.18,20,21 In the present study, H. pylori
infection was found in 26 of 49 (53.1%) HIV-1 immunologic non-
responder patients. In agreement with the previous reports,22,23 all
26 patients had CD4 cell counts of > 100 cells/mm3. Moreover, H.
pylori-infected and uninfected subjects (26 and 23 patients,
respectively) had similar clinical, immunological (CD4/CD8) and
virological (plasma HIV-1 load <400 copies/ml) status. The
duration and nature of HAART as well as the demographic
background and time from HIV diagnosis were also comparable
between H. pylori-positive and negative patients.
The mechanisms by which H. pylori eradication can boost
immune reconstitution in HIV-1-infected patients are not known.As a result of HIV-1 infection, a high proportion of CD4+ T cells are
lost, withmucosal tissues being themost severely affected. Indeed,
the frequency of HIV-1 infection in gut CD4+ T cells is very high,
causing persistent immune activation derived by viral replication
leading to further CD4+ cell depletion.24 We propose that H. pylori
co-infection can further aggravate local and systemic immune
activation in patients with chronic HIV-1 infection.
The main cell target during established HIV-1 infection is the
CCR5+CD4+ activated T lymphocyte.25 CCR5+CD4+ cells are
regularly present in gastric mucosa and their levels increase with
inﬂamed gastric mucosa inﬂammation.26 Studies of the local and
systemic immune responses against H. pylori have led to the
concept that H. pylori infection stimulates monocytes and
macrophages, elicits a predominant Th1 immune response with
an increased expression of CCR5 on T cells (the cellular target for
HIV-1), and down-regulates cytotoxic T cell responses.27–29
Moreover, increased expression of the chemokine receptor
CCR4, another target of HIV-1, in antral and duodenal activated
CD4+ T cells and circulating CD4+CD25high regulatory T cells have
been reported in H. pylori-positive individuals.30–32 Furthermore,
H. pylori infection may stimulate other HIV-1-infected cells,
especially latently infected macrophages, to replicate, as has been
shown for other opportunistic infections.33–36
It should be noted that some H. pylori strains secretes cytotoxin
(VacA), which was recently shown to inhibit human CD4+ cell
activation and proliferation37 via blocking of NFAT (nuclear factor
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HIV-1 infection of primary human CD4+ T cells.39 Thus, H. pylori
eradication may prevent these potentially protective mechanisms.
In the present study we did not measure local (gut) or systemic
(serum) levels of VacA. Furthermore, the real effects of the latter
cytotoxin, if there are any, on the immune system of patients with
HIV-1 and H. pylori co-infection, have not yet been determined.
Resting, non-activated CD4+ cells are quite resistant to HIV-1
infection.40 Following T cell receptor (TCR) activation, the
proliferation and differentiation of CD4+ cells are subsequently
driven by sustained cytokine signals. Both TCR and cytokine signals
can render resting CD4+ cells highly susceptible to HIV-1
infection.41,42 Thus, eradication of H. pylori in HIV-1 patients
probably down-regulates CD4+ activation, reducing HIV-1 infec-
tion of yet unaffected CD4+ cells. The immune reconstitution seen
in our patients following successful H. pylori eradication may be
the result, at least in part, of such a mechanism.
In addition, eradication of H. pylori may affect the immune
system by other mechanisms, such as improving the absorption
and the bioavailability of HAART medications, as was shown
previously for delavirdine,43 and reducing the translocation of
bacterial products that cause immune activation.44
Based on the above studies, which suggest that the H. pylori
infection (regardless of patient symptoms) might harm the
immune system and the rate of immune reconstitution in HIV-1
patients, we offered all our H. pylori-positive HIV-1 patients triple
therapy for H. pylori eradication.
Although we suggest that the immune reconstitution observed
in group 1 patients was due to successful H. pylori eradication, we
cannot rule out other explanations, such as direct immunoregu-
latory effects of the triple therapy with omeprazole, amoxicillin
and clarithromycin45 or the elimination of other (undeﬁned)
pathogenic infections,44 as the basis for the latter effect. Triple
therapy of immunological non-responder HIV-1 patients without
H. pylori infection for two weeks, which was not done in the
present study, may help to clarify this issue.
At the end of the study, 24 months after H. pylori diagnosis and/
or eradication, the CD4 and CD8 levels (counts and percentages) in
group 1 patients were signiﬁcantly higher (CD4) and lower (CD8)
than the levels observed in the same patients during the 12months
preceding H. pylori diagnosis. However, at the end of the study, the
effects were less prominent than at 12–18 months following H.
pylori eradication (Figures 1 and 2). A more prolonged follow-up
period (>24 months) is needed in order to determine whether the
signiﬁcant difference in immune reconstitution observed between
group 1 and group 2 patients is stable or transient. The fact that at
18 months following H. pylori eradication the CD4 cell counts start
to decrease with a parallel increase in CD8 cell counts may reﬂect
H. pylori re-infection of group 1 patients (not tested in our study) or
it may result from various other factors that affect the immune
system in HIV-1-infected patients.
Our study has several limitations. First, the number of patients
in both groups was quite small. Second, the patients were not
randomly assigned to the two study groups. Third, the study was
not blinded, though as outcome parameters were based on
laboratory rather then clinical data, a potential bias is less likely.
One cannot exclude that the patients in group 2, who refused to
take triple therapy for H. pylori eradication, were less adherent to
their HAART medications, though the similar clinical and
immunological parameters during the 12 months preceding H.
pylori diagnosis do not support such an explanation. In addition, as
discussed above, a more prolonged follow-up period is needed in
order to further evaluate the long-term effects of H. pylori
eradication on the immune system of HIV-1-infected patients.
Further studies of larger numbers of HIV-1 patients with and
without H. pylori co-infection for a prolonged period of time areneeded in order to deﬁne the role of H. pylori co-infection and
eradication in immune reconstitution of HAART-treated HIV-1-
infected patients.
Conﬂict of interest: No conﬂict of interest to declare.
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